We last looked at Pfizer (PFE) back on March 8 and wrote that "PFE may continue to hold around $34 and that's okay but the quantitative downgrade to hold and a Point and Figure target of $30 tells us to be careful as we could see a retest of the June low in the weeks ahead. It may not happen but luck favors the prepared."
More from Investing
The strength in the Russell 2000 is a positive sign for stock-picking.
Amid the Fed's shift in tone and the market's reaction, I'm eyeing Apex Technology Acquisition.
Here's what Jim Cramer has to say about the stock.
While the Fed hasn't made any actual rate policy changes, seven Fed members are now predicting a hike in 2022 vs. four previously.